The molecular assay by dPCR was first established to specifically and accurately detect and quantify wild-type BRAF and variant BRAF in DNA from human follicular thyroid carcinoma–derived FTC-133 and papillary thyroid carcinoma–derived BCPAP cells. This evidence concerns the gene BRAF and thyroid gland papillary carcinoma.